JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Kodu・Aktsiate loetelu・Odonate Therapeutics Inc

O
Odonate Therapeutics Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Odonate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 23:53 UTC

Tulu

Naver Posts Weaker First-Quarter Earnings

29. apr 2026, 23:41 UTC

Kuumad aktsiad

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. apr 2026, 23:55 UTC

Tulu

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. apr 2026, 23:54 UTC

Tulu

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. apr 2026, 23:52 UTC

Tulu

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. apr 2026, 23:51 UTC

Tulu

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. apr 2026, 23:22 UTC

Tulu

China Longyuan 1Q Net CNY1.70B, Down 14%

29. apr 2026, 23:22 UTC

Tulu

China Longyuan: Power Generation Down 2.9% as of End-March

29. apr 2026, 23:20 UTC

Tulu

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. apr 2026, 23:20 UTC

Tulu

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss Narrows>000002.SZ

29. apr 2026, 23:18 UTC

Tulu

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. apr 2026, 23:17 UTC

Tulu

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. apr 2026, 23:13 UTC

Tulu

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. apr 2026, 23:12 UTC

Tulu

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. apr 2026, 23:04 UTC

Tulu

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. apr 2026, 23:04 UTC

Tulu

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Võrdlus sarnastega

Hinnamuutus

Odonate Therapeutics Inc Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.